Main > ONCOLOGY (**) > Leukemia>Myeloid>Acute>t-AML or> * > IE. J. Daunorubicin+Cytarabine>

---

IE. J. Daunorubicin+Cytarabine>'s subsections
(*) CA Approval Date: 2021. 07.07
(*) EU Approval Date: 2018. 08.27
(*) USA Approval Date: 2017. 08.03
>Liposome for Inj.
>or AML-MRC
Company
MRC: Myelodysplasia-Related Changes
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 3
Patent>UpDate: 2017. 08.01
t-AML: Therapy-Related AML
TradeMark (Drug)
TradeMark (Drug) Web-Site
TradeMark (Technology)

IE. J. Daunorubicin+Cytarabine>'s products
This section has no products